Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04403139 · ClinicalTrials.gov registry record · Phase 4
VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
A Phase 4 study of Varicella Zoster Virus Infection, sponsored by University of Washington.
- Active
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04403139 is a Phase 4 study of Varicella Zoster Virus Infection that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04403139, a Phase 4 study of Varicella Zoster Virus Infection, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
Conditions Studied
Interventions
- DRUG Shingrix
Study Locations (1)
Washington
- University of Washington Virology Research Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2026-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04403139
The ClinicalTrials.gov registry entry for NCT04403139 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Varicella Zoster Virus Infection appearing as the primary indexed condition, and to 1 intervention - of which Shingrix is the first listed.
NCT04403139 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT04403139 about?
NCT04403139 is a clinical study titled "VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination". To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
What is the current status of trial NCT04403139?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2022-04-27. Estimated completion is 2026-02.
What conditions does trial NCT04403139 study?
This clinical trial studies the following conditions: Varicella Zoster Virus Infection.
What interventions are being tested in trial NCT04403139?
The interventions under investigation include: Shingrix (DRUG).
Who is sponsoring clinical trial NCT04403139?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04403139 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Varicella Zoster Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.